Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials



Rating:

Share or cite this content

Citations should be made in the following way:
L. Sher (Rolling Hills Estates, United States of America), M. Wechsler (Denver, United States of America), K. Rabe (Grosshansdorf & Kiel, Germany), J. Maspero (Buenos Aires, Argentina), N. Daizadeh (Cambridge, United States of America), X. Mao (Bridgewater, United States of America), B. Ortiz (Tarrytown, United States of America), L. Mannent (Chilly-Mazarin, France), E. Laws (Bridgewater, United States of America), M. Ruddy (Tarrytown, United States of America), N. Pandit-Abid (Bridgewater, United States of America), D. Lederer (Tarrytown, United States of America), M. Hardin (Cambridge, United States of America). Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients. 2519

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Short-term effects of pulmonary rehabilitation on asthma control in patients with moderate-severe unstable asthma Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Regarding the role of FENO in predicting failure after ICS reduction in mild-to-moderate asthma patients Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020 Year: 2020 The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 604s Year: 2005 Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020 Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Factors resulting in uncontrolled severe persistent asthma in children Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004 Long-term efficacy of QMF149 in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012